OBJECTIVE: To assess whether oral ketamine is safe at higher dosages for sedating children and whether it may be an option for the control of chronic pain in children. STUDY DESIGN: A prospective study was performed on 12 children with chronic pain to identify the maximum tolerated dosage of oral ketamine. Participants were given 14 days of oral ketamine, 3 times daily, at dosages ranging from 0.25-1.5 mg/kg/dose. Participants were assessed for toxicity and for pain severity at baseline and on day 14 of treatment. RESULTS: Two participants, both treated at 1.5 mg/kg/dose, experienced dose-limiting toxicities (sedation and anorexia). One participant, treated at 1 mg/kg/dose, opted to stop ketamine treatment due to new pain on treatment. Nine participants completed their course of ketamine treatment. Of these 12 children, 5 experienced improvement in their pain scores, 2 with complete resolution of pain, lasting >4 weeks off ketamine treatment. CONCLUSION: Oral ketamine at dosages of 0.25-1 mg/kg/dose appears to be safe when given for 14 days to children with chronic pain.
OBJECTIVE: To assess whether oral ketamine is safe at higher dosages for sedating children and whether it may be an option for the control of chronic pain in children. STUDY DESIGN: A prospective study was performed on 12 children with chronic pain to identify the maximum tolerated dosage of oral ketamine. Participants were given 14 days of oral ketamine, 3 times daily, at dosages ranging from 0.25-1.5 mg/kg/dose. Participants were assessed for toxicity and for pain severity at baseline and on day 14 of treatment. RESULTS: Two participants, both treated at 1.5 mg/kg/dose, experienced dose-limiting toxicities (sedation and anorexia). One participant, treated at 1 mg/kg/dose, opted to stop ketamine treatment due to new pain on treatment. Nine participants completed their course of ketamine treatment. Of these 12 children, 5 experienced improvement in their pain scores, 2 with complete resolution of pain, lasting >4 weeks off ketamine treatment. CONCLUSION: Oral ketamine at dosages of 0.25-1 mg/kg/dose appears to be safe when given for 14 days to children with chronic pain.
Authors: D J Smith; R L Bouchal; C A deSanctis; P J Monroe; J B Amedro; J M Perrotti; T Crisp Journal: Neuropharmacology Date: 1987-09 Impact factor: 5.250
Authors: G S Falchook; M Duvic; D S Hong; J Wheler; A Naing; J Lim; R Kurzrock Journal: Cancer Chemother Pharmacol Date: 2011-12-29 Impact factor: 3.333
Authors: Y L Chen; V Le Vraux; A Leneveu; F Dreyfus; A Stheneur; I Florentin; M De Sousa; J P Giroud; B Flouvat; L Chauvelot-Moachon Journal: Clin Pharmacol Ther Date: 1994-06 Impact factor: 6.875
Authors: Thiago R L Romero; Giovane S Galdino; Grazielle C Silva; Lívia C Resende; Andréa C Perez; Steyner F Côrtes; Igor D G Duarte Journal: Anesth Analg Date: 2011-07-25 Impact factor: 5.108
Authors: Charles B Berde; Gary A Walco; Elliot J Krane; K J S Anand; Jacob V Aranda; Kenneth D Craig; Carlton D Dampier; Julia C Finkel; Martin Grabois; Celeste Johnston; John Lantos; Alyssa Lebel; Lynne G Maxwell; Patrick McGrath; Timothy F Oberlander; Laura E Schanberg; Bonnie Stevens; Anna Taddio; Carl L von Baeyer; Myron Yaster; William T Zempsky Journal: Pediatrics Date: 2012-01-16 Impact factor: 7.124
Authors: Kathy A Sheehy; Elena A Muller; Caroline Lippold; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado Journal: BMC Pediatr Date: 2015-12-01 Impact factor: 2.125
Authors: Amy Lee Bredlau; Brian T Harel; Michael P McDermott; Robert H Dworkin; David N Korones; James G Dolan; Heather R Adams Journal: J Palliat Care Med Date: 2015-03-27